Tyrosine Kinase Inhibitors: all 10,469 studies that test it
Page 17 of 105. Open to participants first (1,907), then studies with results posted, then the rest; newest registration first within each.
- Stand UP to Rheumatoid Arthritis (SUPRA)RecruitingNCT05305066Not applicable
- A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid LeukemiaRecruitingNCT05304377Phase 1
- Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung CancerRecruitingNCT05296603Phase 2
- Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast CancerRecruitingNCT05296577Phase 2
- Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast CancerRecruitingNCT05292742Phase 2
- ZR-CHOP in DLBCL With Specific Gene AbnormalityRecruitingNCT05290337Phase 2
- ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCLRecruitingNCT05290090Phase 2
- Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis.Not yet recruitingNCT05286320Phase 1/2
- Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor TherapyRecruitingNCT05283226Phase 2
- Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)RecruitingNCT05281406Phase 2
- Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to RuxolitinibRecruitingNCT05280509Phase 1/2
- First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R MutationsRecruitingNCT05271916Phase 1/2
- Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung CancerRecruitingNCT05267288Phase 2
- Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine TumorsRecruitingNCT05263050Phase 2
- To Evaluate KC1036 in the Patients with Advanced Digestive System TumorsRecruitingNCT05260385Phase 1/2
- Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell LymphomaRecruitingNCT05256641Phase 1/2
- A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)RecruitingNCT05254743Phase 3
- A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal CancerRecruitingNCT05253651Phase 3
- TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCCRecruitingNCT05250843Phase 2/3
- SPH5030 Tablets in Subjects With Advanced Her2-positive Solid TumorsRecruitingNCT05245058Early Phase 1
- Cabo-POLARIS : A Trial to Evaluate Cabozantinib Among Haemodialysied PatientsNot yet recruitingNCT05241561Phase 2
- Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung CancerRecruitingNCT05241028Phase 2
- A Phase II Clinical Study of Surufatinib Combined With Sintilimab in the Treatment of Advanced Gastric CancerRecruitingNCT05235906Phase 2
- A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell LymphomaRecruitingNCT05234684Phase 3
- Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRCRecruitingNCT05229003Phase 2
- Pyrotinib Maleate, Trastuzumab, SHR6390 and Letrozole in Combination for Stage II-III TPBCRecruitingNCT05228951Phase 2
- Safety and Efficacy of Lenvatinib and Anti-PD1 Antibody Combined With Radiotherapy Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTTRecruitingNCT05225116Phase 1
- SOLIDARITY Finland Plus Long-COVIDRecruitingNCT05220280Phase 4
- Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic CancerRecruitingNCT05218889Phase 1/2
- Exosomes Detection for the Prediction of the Efficacy and Adverse Reactions of Anlotinib in Patients With Advanced NSCLCNot yet recruitingNCT05218759Not applicable
- Anlotinib Plus PD-1 Inhibitor as 2nd-line Threapy in Patients With Metastatic Pancreatic CancerRecruitingNCT05218629Phase 2
- A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune ThrombocytopeniaRecruitingNCT05214391Phase 2
- Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT05214222Phase 2
- Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System LymphomaRecruitingNCT05209620Phase 2
- (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal TumorsRecruitingNCT05208047Phase 3
- Phase Ⅰ/Ⅱ Study of the HS-10365 in Patients With Advanced Solid TumorsRecruitingNCT05207787Phase 1/2
- A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus CrizotinibNot yet recruitingNCT05204628Phase 3
- Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary ThrombocytopeniaRecruitingNCT05199909Phase 2
- Study of Camrelizumab in Combination With Apatinib Mesylate Plus Albumin-bound Paclitaxel and Cisplatin as the First Line Treatment of Recurrent or Metastatic, UnresectableHead and Neck Squamous Cell CarcinomaNot yet recruitingNCT05189184Phase 2
- First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural MesotheliomaRecruitingNCT05188859Phase 2
- An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast CancerRecruitingNCT05186545Phase 2
- A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung CancerNot yet recruitingNCT05186506Phase 2
- Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)RecruitingNCT05185739Phase 2
- A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative ColitisRecruitingNCT05181137Phase 3
- Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 InhibitorRecruitingNCT05181033Phase 2
- Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsRecruitingNCT05176483Phase 1
- Zanubrutinib and Venetoclax in CLL (ZANU-VEN)RecruitingNCT05168930Phase 2
- Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung CancerRecruitingNCT05168566Phase 2
- Preoperative IMRT With Anlotinib and Penpulimab for Localized Sarcoma （SPARE-01）RecruitingNCT05167994Phase 2
- Radiofrequency Ablation Combined With Toripalimab and Lenvatinib in the Treatment of Short-term Recurrent Hepatocellular Carcinoma.Not yet recruitingNCT05162898Not applicable
- The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer DrugsRecruitingNCT05159245Phase 2
- Extension Study of Infigratinib in Children With Achondroplasia (ACH)Enrolling by invitationNCT05145010Phase 2
- A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid TumorsRecruitingNCT05135975Phase 2
- A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AMLRecruitingNCT05133882Phase 1/2
- Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung AdenocarcinomaNot yet recruitingNCT05132985Phase 2
- A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal CancerRecruitingNCT05128825Phase 2
- A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)RecruitingNCT05118789Phase 1/2
- Zanubrutinib Monotherapy in Relapsed/Refractory Central Nervous System LymphomaRecruitingNCT05117814Not applicable
- Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian CancerRecruitingNCT05113368Phase 2
- Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial CancerRecruitingNCT05112991Phase 2
- Tofacitinib Versus Cyclosporine for Steroid Refractory Acute Severe Ulcerative ColitisNot yet recruitingNCT05112263Not applicable
- A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung CancerRecruitingNCT05104788Phase 2
- Comparison of Tofacitinib and Methotrexate in Takayasu's ArteritisRecruitingNCT05102448Phase 4
- Cryoablation Combined with Sintilimab Plus Lenvatinib in Previously Treated Unresectable Liver Metastasis from Solid TumorsRecruitingNCT05098847Phase 2
- Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung CancerRecruitingNCT05098210Phase 1
- Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or ThoraxRecruitingNCT05092373Phase 1
- The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast CancerRecruitingNCT05075512Phase 2
- Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain MetastasesRecruitingNCT05064280Phase 2
- Cryoablation Combined with Tislelizumab Plus Lenvatinib As Second-line or Later Therapy in Advanced Hepatocellular CarcinomaRecruitingNCT05057845Phase 2
- Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver MetastasisRecruitingNCT05057052Phase 2
- Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine TumorsRecruitingNCT05048901Phase 1/2
- A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain MetastasesRecruitingNCT05048212Phase 2
- Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular CarcinomaRecruitingNCT05048017Phase 2
- A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung CancerRecruitingNCT05042375Phase 3
- Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic CholangiocarcinomaNot yet recruitingNCT05039892Phase 2
- COAST Therapy in Advanced Solid Tumors and Prostate CancerRecruitingNCT05036226Phase 1/2
- A Phase II Study of Anlotinib Combined With Penpulimab in Subjects With Gynecological CancerRecruitingNCT05028504Phase 2
- Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AMLRecruitingNCT05024552Phase 1
- Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid TumorsRecruitingNCT05024214Phase 1/2
- Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS StudyRecruitingNCT05019703Phase 2
- Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast CancerRecruitingNCT05019690Phase 1/2
- A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine CarcinomaRecruitingNCT05015621Phase 3
- ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell CarcinomaRecruitingNCT05014464Phase 2
- Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLCRecruitingNCT05011487Phase 2
- Lenvatinib Plus Sintilimab in Patients with Immune Checkpoint Inhibitor Previously Treated Advanced Liver CancerRecruitingNCT05010681Phase 2
- ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeRecruitingNCT05010122Phase 1/2
- A Study of Ruxolitinib and Duvelisib in People With LymphomaRecruitingNCT05010005Phase 1
- Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)RecruitingNCT05009927Phase 2
- Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung CancerRecruitingNCT05004974Phase 2
- A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor CancerRecruitingNCT05004116Phase 1/2
- ConsideRAte Study - Splenic Stimulation for RARecruitingNCT05003310Not applicable
- Atezolizumab Plus Tivozanib in Immunologically Cold Tumor TypesRecruitingNCT05000294Phase 1/2
- (Apex) Bezuclastinib in Patients With Advanced Systemic MastocytosisRecruitingNCT04996875Phase 2
- A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid TumorsRecruitingNCT04996121Phase 1/2
- A Study of LP-168 in Participants With Relapse or Refractory B-Cell LymphomaRecruitingNCT04993690Phase 1
- Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)RecruitingNCT04989621Phase 2
- Better After CHoosing. Randomly Allocated or Patient Preference Based Treatment With Filgotinib or TNFi in RA (BACH)RecruitingNCT04985435Phase 4
- Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney CancerRecruitingNCT04981509Phase 2
- Efficacy of Nintedanib for Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) PatientsRecruitingNCT04976036Phase 2
- Tyrosine Kinase Inhibitors in Metastastic Adenoid Cystic CarcinomaRecruitingNCT04974866Phase 2